JAKARTA - Holding BUMN Pharmaceuticals (Bio Farma, Kimia Farma and Indofarma) will enter a new phase in business development. Especially after it managed to improve its performance with a record revenue rising 203.16 percent to Rp43.44 trillion and earning a net profit of Rp1.93 trillion or skyrocketing 668.1 percent in 2021.
President Director of Bio Farma Honesti Basyir said that this significant increase in performance was one of the contributions of Bio Farma's success in carrying out assignments for the supply and distribution of COVID-19 vaccines. In addition, there is also a contribution from the sale of Bio Farma's regular services in the form of vaccines and serums for the domestic and international markets.
"The encouraging performance of the Pharmaceutical BUMN Holding in 2021 is expected to continue in 2022, where the Pharmaceutical BUMN Holding is transforming into the healthcare industry and digitizing health services," Honesti said in his statement, Tuesday, June 21.
Since it was formed in 2020, Holding BUMN Pharmaceuticals has carried a mission to realize national health resilience in Indonesia, by integrating all of its competencies, combining all talents and abilities to innovate and preparing transformation programs as a roadmap for the development of Pharmaceutical SOEs into a class Leading Life Science Company. world.
Holding BUMN Pharmaceuticals since the beginning of the COVID-19 pandemic has also played a role as the front line in preventing and overcoming the pandemic by providing, developing, producing and distributing COVID-19 vaccines to all corners of the country, so that the goal of establishing herd immunity can be achieved.
Honesti added that the vaccine is a game changer, to help the Indonesian people get out of the problems of the COVID-19 pandemic. Bio Farma, as the holding company for Pharmaceutical SOEs, received a vital and strategic assignment from the government to ensure the distribution of 400 million doses of COVID-19 vaccine while maintaining the highest quality standards from the WHO.
The work of Bio Farma and its subsidiaries in this war is a form of commitment from the Pharmaceutical SOEs to carry out a strategic role in maintaining the stability of the supply and distribution of vaccines nationally.
In addition to vaccines and serum, sales of the BUMN Pharmaceutical Holdings were also supported by sales of subsidiaries, PT Kimia Farma in the manufacturing sector and Indofarma, which came from increased sales value from the drug product segment and the procurement of COVID-19 vaccines.
"Bio Farma's performance as the parent, contributed by the government sector through the assignment of providing COVID-19 vaccines, amounted to IDR 26.81 trillion, followed by the export sector which was quite significant reaching IDR 1.47 trillion, an increase of 47.58 percent compared to 2020, and distribution of COVID-19 vaccine grants amounting to Rp388.83 billion," said Honesti.
Meanwhile, Kimia Farma (KAEF) as a member of the Pharmaceutical BUMN Holding, contributed 29.6 percent of the total net income, or reached Rp 12.85 trillion. Kimia Farma's sales were dominated by an increase in the manufacturing segment which grew by 246.75 percent, and the retail segment which grew 19.12 percent from the previous year.
Indofarma (INAF) contributed 6.68 percent or reached Rp 2.9 trillion, or an increase of 69.15 percent. This achievement came from an increase in the sales value of the drug product segment by Rp. 2.1 trillion, an increase of Rp. 1.23 trillion or 142.52 percent compared to 2020 of Rp. 865.86 billion. Where the procurement of the COVID-19 vaccine contributed to net sales of Rp.924.76 billion.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
